Clinical Trial Update: Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating efficacy and safety of IBI308 in relapsed/refractory classical Hodgkin's lymphoma completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• IBI308 (IBI308)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Relapsed/Refractory Classical Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-12-07